The new horizon for cardiac therapy may lie beneath the surface, with the downstream mediators of G proteincoupled receptor (GPCR) activity. Targeted approaches have shown that receptor activation may be biased toward signaling through G proteins or through GPCR kinases (GRKs) and b-arrestins, with divergent functional outcomes. In addition to these canonical roles, numerous noncanonical activities of GRKs and b-arrestins have been demonstrated to modulate GPCR signaling at all levels of receptor activation and regulation. It has been appreciated for some time now that there are at least 2 primary mechanistic signaling
GPCR KINASES
GPCR signaling is tightly controlled by cytosolic GRKs.
Canonically, GRKs translocate to or target agonistbound GPCRs where they phosphorylate the receptor, facilitating b-arrestin recruitment for desensitization and internalization of receptors. A thorough review of GRK structure, localization, GPCR activity, cardiac function, and regulation has recently been published (7) , highlighting how GRKs control GCPR signal duration and impact. Continued research into the regulation, distribution, and noncanonical signaling of cardiac GRKs has demonstrated expanding roles in both normal cardiac function and cardiovascular disease (Central Illustration) (8) (9) (10) (11) . A more thorough understanding of the functional consequences of GRK activities in the heart will allow for targeted approaches for GRK modulation in human therapy.
Despite a high level of shared sequence identity and the same tissue distribution as GRK2, GRK3 has been observed to participate in the regulation of thrombin, endothelin, and a 1 -adrenergic receptor (a 1 AR) activity in the heart. Although cardiac GRK3 levels are not altered during human HF, these data suggest that it may play a role in cardiac growth and hypertrophy (12, 13 The full functional significance for GRK3 in cardiomyocyte signaling in the heathy heart and during pathophysiological conditions remains to be elucidated and is as yet not a target for HF therapy. (34, 35) . Together, these data present a dichotomy, wherein the noncanonical nuclear translocation of GRK5 produces pathological signaling, whereas GRK5 activity at membrane-bound GPCRs may be protective. This is an important consideration regarding the therapeutic potential of GRK5, and suggests that targeting the cellular localization of GRK5 may be more effective than a kinase inhibitor. In fact, a small molecular inhibitor of GRK5 has already been developed and was used to gain a high-resolution crystal structure for bovine GRK5 (36) , which will allow for the investigation of allosteric modulation of GRK5 and may provide a means to differentially target nuclear translocation versus kinase activity. The role of GRK5 in the regulation cardiac signaling in the healthy and diseased myocardium and the pursuit for therapeutic inhibition of GRK5 has recently been reviewed in detail (37) .
Despite the wealth of knowledge regarding the role of GRK2 in cardiovascular function, the full scope and impact of GRK2 regulation in cardiac physiology and disease is still being defined. Ongoing research continues to identify new interacting partners and Grisanti et al.
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The AT 1 R is of interest for the treatment of HF due to its role in the development and progression of cardiac dysfunction. G protein-mediated signaling through Gaq causes vasoconstriction (91, 92) and hypertension, whereas in the heart it causes hypertrophy (6, 91) . Together, these positive findings for the potential use of b-arrestin-biased AT 1 R agonists for ameliorating various HF etiologies led to a randomized,
J A C C : B A S I C T O T R A N S L A T I O N A L SCIENCE VOL. 3, NO. 4, 2018
Grisanti et al. Grisanti et al.
APELIN-APJ SYSTEM
A newly identified GPCR system of therapeutic interest in the cardiovascular system is the apelin-APJ system. Apelin was discovered in 1998 as an endogenous ligand for the previously orphan receptor APJ, which shows homology and similar tissue distribution as the AT 1 R (136,137) . Apelin is synthesized as preproapelin and cleaved by angiotensin-converting enzyme into several shorter, active fragments that appear to differ in their ability to activate, internalize, and recycle the receptor (136, 138) . APJ is a Gi-coupled GPCR, with potential coupling to Gq (136, 139, 140) . In Apelin-APJ are also thought to play a role in cardiac dysfunction. Patients show elevations in plasma apelin in patients with early (148, 149) , which is decreased in later stages (148, 150) . In murine models of ischemic HF, acute up-regulation of apelin and APJ occurs following ischemic injury and these elevations in expression persist long-term (151) (152) (153) . APJ and apelin knockout mice have impairments in contractility (154, 155) and impaired healing following ischemia-reperfusion (156) . Furthermore, administration of apelin or stable apelin analogs protects against ischemia-reperfusion in rodent models of ischemic heart disease, supporting the therapeutic potential of targeting apelin-APJ for treatment of HF (156) (157) (158) (159) (160) . However, the effects of biased ligands in this receptor system remains to be determined.
UROCORTIN-CRF SYSTEM
Another GPCR system that is gaining ground as a 
